Fifth Third Bancorp Bei Gene, Ltd. Transaction History

Fifth Third Bancorp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 24, 2023	BUY	$215.53 - $274.5 $1,077 - $1,372	5 New	5 $1,000
Q3 2022 Oct 25, 2022	BUY	$131.8 - $202.24 $395 - $606	3 Added 100.0%	6 $1,000
Q2 2022 Aug 04, 2022	BUY	$121.11 - $216.05 $363 - $648	3 New	3 $0
Q4 2019 Feb 14, 2020	SELL	$115.78 - $208.34 $2,315 - $4,166	-20 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$120.61 - $148.29 $2,050 - $2,520	17 Added 566.67%	20 $2,000
Q2 2019 Aug 07, 2019	BUY	$113.99 - $146.86 $341 - $440	3 New	3 $0

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

Stay updated on Fifth Third Bancorp with notifications on news.